Loading...
Market
What will Pfizer's dividend yield be at the end of 2024?
3
Resolution / Starting Odds
Less than 5% • 25%
5% to 5.5% • 25%
5.5% to 6% • 25%
Greater than 6% • 25%
Pfizer's financial statements and announcements
Story
Ex-Pfizer CEO Read and CFO D'Amelio Back CEO Bourla, Exit Starboard's Activist Campaign
Oct 10, 2024, 01:31 AM
Former Pfizer CEO Ian Read and former CFO Frank D'Amelio have withdrawn their support for activist investor Starboard Value's campaign against Pfizer, declaring they are "fully supportive" of current CEO Albert Bourla, senior management, and the board. The two executives had initially teamed up with Starboard to address Pfizer's lack of focus, but their unexpected reversal leaves the activist campaign struggling without backing from former company insiders. This development comes as Starboard Value, which has purchased $1 billion worth of Pfizer shares, has been increasing pressure on the pharmaceutical giant following concerns over its performance after the COVID-19 crisis. Investors note that Pfizer offers a dividend yield of 5.5%, making it attractive to some despite recent challenges.
View original story
Similar markets
Negative growth • 25%
0-5% growth • 25%
5-10% growth • 25%
Over 10% growth • 25%
Increase by more than 5% • 25%
Increase by up to 5% • 25%
Decrease by up to 5% • 25%
Decrease by more than 5% • 25%
$2.80 - $2.85 • 25%
$2.86 - $2.90 • 25%
$2.91 - $2.95 • 25%
$2.96 - $3.00 • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Less than 20% • 25%
20% to 30% • 25%
30% to 40% • 25%
More than 40% • 25%
Outperform by more than 5% • 25%
Perform within 5% of S&P 500 • 25%
Underperform by 1-5% • 25%
Underperform by more than 5% • 25%
Outperforms by more than 5% • 25%
Outperforms by 0% to 5% • 25%
Underperforms by 0% to 5% • 25%
Underperforms by more than 5% • 25%
Outperforms S&P 500 • 25%
Matches S&P 500 • 25%
Underperforms S&P 500 • 25%
Significantly underperforms • 25%
